Abstract
The prevalence of allergic diseases has increased during the last decades (Burr et al. 64
1989, Asher et al. 2006). Genetic factors are important for allergy development, but a 65
time period of 30-40 years is considered to be to short for human genetic 66 composition to undergo such dramatic changes causing this increasing prevalence. 67
As a consequence, a lot of attention has been drawn to the postnatal exposure to 68 environmental factors associated with a westernized lifestyle. Exposure to 69 environmental factors important for allergy development appears to be important very 70 early in life, perhaps even before birth (Jenmalm and Bjorksten 1998) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 The aim of the present study was to analyze the cytokines IL-2, IL-4, IL-6, IL-10, IL-123 13, IFN-γ, Tumor necrosis factor (TNF), the chemokines CXCL10, CXCL11, CCL17, 124 CCL22 and histamine release in placentas after stimulation with apple allergen or the 125 mast cell degranulating compound 48/80 in relation to maternal allergic disease. 126 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 7
Material and methods 128

Subjects 129
Four women with an oral allergy syndrome displaying allergic symptoms to apple and 130 5 women without any allergic symptoms from the Jena area, region of Thuringia, 131
Germany, were included in the study. The following inclusion criteria were applied: 132 delivery after week 37 of pregnancy, a healthy appropriately grown newborn, 133 absence of maternal chronic metabolic diseases, pharmacological therapy and 134 pregnancy complications. In their anamneses, none of the allergic patients has 135 reported systemic reactions, but only the classical local reactions as described for the 136 oral allergy syndrome (Ortolani et al. 1988) . The similar severity of described 137 symptoms did not allow subdivision of the patients group. All study participants gave 138 their written informed consent. did not lead to exclusion. Both of the rapid diagnosis allergy tests were also used to 149 exclude allergic sensitisation in the anamnestically non-allergic women. The 150 sensitivity and specificity of the Auro-Dex Visual-Ens has been assessed previously 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 8 Three of the four allergic women had in our laboratory a positive IgE test to apple or 153 birch (CAP class II-V) and the fourth patient showed a medical certificate for 154 confirmation of sensitisation to apple (CAP class II). CAP classes could not be used 155 for defining subgroups due to the limited availability of placentas from allergic 156 individuals. None of the non-allergic women were sensitised to the analysed 157 allergens. The concentration has been determined as described previously (Vieths et al. 1994 , 10 amoxillin (250 mg/l; Sigma-Aldrich), heparin (500 µl/l, equivalent to 2500 IU/l, 203
Ratiopharm, Ulm, Germany) and dextran FP40 (10 g/l, Serva, Heidelberg, Germany), 204 adjusted to an pH of 7,4 by NaOH (Roth, Karlsruhe, Germany). For perfusion, the 205 medium was warmed up to 37°C and oxygenated by using a Silox-S oxygenator 206 (Mera Senko Medical Instrument, Tokyo, Japan). The flow rate was 2.2 ml/min during 207 the entire perfusion period. The experimental cotyledon was perfused with pure 208 perfusion medium for 1 h followed by medium containing 4 µg/ml protocol and the excitation wave lengths were adapted to the analysis of perfusion 225 medium. Histamine was extracted from 0.5 ml perfusion medium by using a mixture 226 of 0.5 ml 0.9% NaCl (Roth), 2.5 ml n-butanol (Roth) and 0.2 ml 3 M NaOH. After 31  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 min incubation on a shaker, the mixture was centrifuged at 900 g for 20 min. Two ml 228 of the butanol-phase was removed and mixed with 1.2 ml 0.12 M HCl and 3.8 ml n-229 heptan (Roth). After 1 min incubation on a shaker, followed by a centrifugation at 600 230 g for 5 min, the n-heptan-phase was removed, cooled on ice, and mixed with 0.4 ml 231 0.75 M NaOH (Roth) and 0.12 ml methanolic o-phthalaldehyde (OPT; Sigma-232 Aldrich). After 4 min incubation, the reaction was terminated by addition of 0.2 ml 2 M 233 H 3 PO 4 on ice. The fluorescence was measured at Ex=355nm; Em=440nm using 234 the Fluorescenence HPLC Monitor RF_551 (Shimadzu, Duisburg, Germany) with 235 40% MeOH/aqua dest. as eluent. The fluorescence data were acquired and 236 calculated using Chromeleon-software (Dionex, Germering, Germany). The standard 237 curve was done in duplicates and ranged from 0.5 to 50 ng/ml (dilution steps: 0; 0.5; 238 1; 3; 5; 10; 20; 50 ng/ml; R 2 > 0.998) and revealed a lower detection limit of 5 ng/ml. 239
The coefficient of variance (CV) was below 1.5%. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12 diluted (1:1) from 5000 to 20 pg/ml for each cytokine. The beads were washed, 253 spinned down (200 g, 5 min), and after removement of supernatants, measured on a 254 flow cytometer (FACS Calibur; BD Bioscience) by using the implemented FCAP 255
Array v1.0.1. kit software with 5-parametric-curve fitting. The sensitivity limits were 256 2.6 pg/ml for IL-2, 2.6 pg/ml for IL-4, 3 pg/ml for IL-6, 2.8 pg/ml for IL-10, 2.8 pg/ml for 257 TNF and 7.1 pg/ml for IFN-γ. The CV was below 10%. The levels of CXCL10, CXCL11, CCL17, CCL22 and IL-13 in the perfusion medium 262
were measured using an in-house multiplex Luminex assay, as described in detail were added to each well of a 1.2 μm pore-size filter plate (Millipore multiscreen, 271
Millipore Corporation, Bedford, USA) and incubated over night with either 272 recombinant human CXCL10, CXCL11, CCL17, CCL22 and IL-13 (R&D Systems), or 273 samples diluted 1:2. The microspheres were washed, incubated for 1 h with 274 biotinylated anti-human CXCL10 (1000 ng/ml, clone 6D4, BD Biosciences), CXCL11 275 (500 ng/ml, BAF320, R&D Systems), CCL17 (500 ng/ml, BAF364, R&D Systems) ,1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 Sanquin) antibody, followed by incubation with 1 μg/ml Streptavidin R-phycoerythrin 278 conjugate (Molecular Probes, Eugene, USA) for 30 minutes. A Luminex 100 instrument 279 (Biosource, Nivelles, Belgium) was used for analysis of the samples and the data 280 acquisition was performed using the StarStation 2.3 software (Applied cytometry 281 systems, Sheffield, UK) with 5-parametric-curve fitting. The sensitivity limits were 6 282 pg/ml for CXCL10 and CXCL11, 1 pg/ml for CCL17 and CCL22 and 8 pg/ml for IL-13. 283
The samples were analyzed in duplicates and the CV was below 15%. Undetectable 284 levels were given the value of the half cut-off. To determine if mast cells in the placenta are able to degranulate, two placentas from 303 non-allergic mothers were perfused with compound 48/80. When this was added as a 304 bolus to the placenta 60 minutes after the beginning of perfusion, a strong histamine 305 release was immediately detectable (Fig 1) . After this rapid response to compound 306 48/80, the histamine levels decreased to basis level, followed by a second increase 307 of histamine release after 3 hours, albeit no further compound 48/80 was added. 308
The chemokines CXCL10, CXCL11, CCL17 and CCL22 (Fig 2A-D) were also 309 released rapidly after mast cell activation with compound 48/80, but not IL-6 (Fig 2E)  310 and TNF (Fig 2F) . 311
312
When 0.1 mg/ml compound 48/80 was permanently added to the perfusion medium, 313 histamine levels were very low and only sporadically detectable during the analysed 314 time period. In analogy to the bolus application, at the initiation of perfusion with 315 compound 48/80, a rapid release of the chemokines CXCL10, CXCL11, CCL17 and 316 CCL22, but not of the cytokines IL-2, IL-4, IL-13, IFN-, IL-6 and TNF was observed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 15
Allergen induced cytokine and chemokine release 320
The activity and stability of the apple allergen preparation has been demonstrated 321 previously by performing series of analyses including SDS-PAGE, two-dimensional 322 electrophoresis, immunoblotting, RAST inhibition, and prick test (Rudeschko et al.  323   1995a, Rudeschko et al. 1995b) . Perfusion of placentas with apple allergen induced 324 a time-dependent increase of IL-6 (Fig 3A) and TNF (Fig 3B) as compared to the 325 unstimulated cotyledon, in placentas of women with apple allergy. The stronger 326 increase after stimulation could be confirmed by a significant interaction between 327 time and allergen for TNF (F (1,125) =16.6, p<0.001) and IL-6 ( F (1,116) =25.1, p<0.001) in 328 the mixed model analyses. IL-6 and TNF were also released spontaneously from 329 placentas of non-allergic women, but without further increase after instillation of apple 330 allergen. The CCL17 levels were slightly elevated after allergen stimulation in 331 placentas of women without apple allergy (Fig 3C) , but the effect was not statistically 332 24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 and IL-13, were undetectable in the majority of the samples. Thus, low levels of these 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 18 circulation, probably explaining the high chemokine levels in the beginning (time point 390 0) of the perfusion experiment (Fig 3A-D) . Only approximately 50% of the samples 391 had detectable levels of CCL17 during the course of perfusion, which indicates that 392 its physiological source is outside the placenta. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 19 prostaglandin production, indicating that mast cell degranulation in the reproductive 415 tract needs to be strictly regulated (reviewed in (Menzies et al. 2011) ). In the here 416 applied placenta perfusion system, histamine release was not induced by tissue 417 perfusion with apple allergen. It may be argued that too little bioactive apple allergen 418 concentrations have reached the mast cells. This may be due to dilution of allergens 419 or to filter effects of tissue barriers, but also to influences on the stability of apple (Fig 3B and 3D) , whereas after approximately 3 h, the 449 concentrations of CXCL10 (Fig 3A) and CCL17 (Fig 3C) have decreased to levels 450 similar to the control cotyledon. Thus, our data possibly indicate a rapid release of 451 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 21
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The table shows the median (first row), minimum (second row) and maximum (third row) levels of TNF, IL-6 and CCL17 in the placenta outflow medium divided to the cotyledon size ((pg/ml)/kg) from placentas of allergic and non-allergic women with and without allergen stimulation. 
